Spirogen Ltd.
Cambridge Research BioVentures Ltd. (CRB), backed by Research Corporation Technologies, was the lead investor in Spirogen Ltd., a London-based company developing new gene-targeting technology.
Spirogen is commercializing a platform technology capable of discovering lead compounds that target any gene sequence. The company's work on new agents that can recognize and interact with any specified gene sequence has widespread applications in the fields of biotechnology, cancer and virology.
Other Spirogen investors include Cambridge Research & Innovation Ltd. (CRIL), Xenva Ltd. and Bloomsbury Investment Capital, the investment arm of University College London (UCL). Cancer Research Campaign Technologies (CRCT), UCL and the Universities of Portsmouth and Nottingham are also Spirogen shareholders.
Inventors/Founders
Prof. David Thurston, and Philip Howard, Ph.D., University of Nottingham, and John Hartley, Ph.D., University College London
SpiroGen Contact
Chris Martin, Spirogen CEO, +44 (0) 207 278 0555
RCT Contact
Shaun A. Kirkpatrick, President & CEO